Phase II trial of continuous treatment with sunitinib in patients with high-risk (BCG-refractory) non-muscle invasive bladder cancer

H Zahoor, MC Mir, PC Barata, AJ Stephenson… - Investigational new …, 2019 - Springer
Purpose Sunitinib is a vascular endothelial growth factor receptor (VEGFR) inhibitor with
antitumor activity against bladder cancer. We hypothesized that treatment with sunitinib may …
被引用次数：25 相关文章

Phase II trial of continuous treatment with sunitinib in patients with high-risk (BCG-refractory) non-muscle invasive bladder cancer

H Zahoor, MC Mir, PC Barata… - Investigational New …, 2019 - search.proquest.com
Purpose Sunitinib is a vascular endothelial growth factor receptor (VEGFR) inhibitor with
antitumor activity against bladder cancer. We hypothesized that treatment with sunitinib may …

Phase II trial of continuous treatment with sunitinib in patients with high-risk (BCG-refractory) non-muscle invasive bladder cancer.

H Zahoor, MC Mir, PC Barata… - Investigational new …, 2019 - europepmc.org
Purpose Sunitinib is a vascular endothelial growth factor receptor (VEGFR) inhibitor with
antitumor activity against bladder cancer. We hypothesized that treatment with sunitinib may …

Phase II trial of continuous treatment with sunitinib in patients with high-risk (BCG-refractory) non-muscle invasive bladder cancer

H Zahoor, MC Mir, PC Barata… - Investigational …, 2019 - pubmed.ncbi.nlm.nih.gov
Purpose Sunitinib is a vascular endothelial growth factor receptor (VEGFR) inhibitor with
antitumor activity against bladder cancer. We hypothesized that treatment with sunitinib may …